These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36064563)

  • 21. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
    Blauvelt A; Chiricozzi A; Ehst BD; Lebwohl MG
    Adv Ther; 2023 Aug; 40(8):3410-3433. PubMed ID: 37330926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study.
    Hamm C; Ramsoondar N; McGillis M; Waugh M; Gooderham M; Giroux LL
    J Cutan Med Surg; 2023; 27(5):476-480. PubMed ID: 37559454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
    Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
    J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis.
    Elgaard CDB; Iversen L; Hjuler KF
    J Dermatolog Treat; 2023 Dec; 34(1):2133531. PubMed ID: 36200762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
    Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
    Graier T; Salmhofer W; Jonak C; Weger W; Kölli C; Gruber B; Sator PG; Prillinger K; Mlynek A; Schütz-Bergmayr M; Richter L; Ratzinger G; Painsi C; Selhofer S; Häring N; Wippel-Slupetzky K; Skvara H; Trattner H; Tanew A; Inzinger M; Tatarski R; Bangert C; Ellersdorfer C; Lichem R; Gruber-Wackernagel A; Hofer A; Legat F; Schmiedberger E; Strohal R; Lange-Asschenfeldt B; Schmuth M; Vujic I; Hoetzenecker W; Trautinger F; Saxinger W; Müllegger R; Quehenberger F; Wolf P
    Br J Dermatol; 2021 Jun; 184(6):1094-1105. PubMed ID: 33289075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
    van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
    Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
    Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
    Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
    Narcisi A; Valenti M; Gargiulo L; Ibba L; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Girolomoni G; Guarneri C; Loconsole F; Sampogna F; Travaglini M; Malagoli P; Costanzo A
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):93-103. PubMed ID: 36156312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
    Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
    Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
    Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
    Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
    Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-IL 23 biologics for the treatment of plaque psoriasis.
    Vu A; Ulschmid C; Gordon KB
    Expert Opin Biol Ther; 2022 Dec; 22(12):1489-1502. PubMed ID: 36243011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.
    Tonini A; Gualtieri B; Panduri S; Romanelli M; Chiricozzi A
    Expert Opin Biol Ther; 2018 Feb; 18(2):135-148. PubMed ID: 29103330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
    Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
    Gargiulo L; Ibba L; Malagoli P; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Megna M; Mercuri SR; Travaglini M; Costanzo A; Narcisi A
    Front Immunol; 2023; 14():1341708. PubMed ID: 38274801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
    Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
    Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
    Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
    Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.